6533b857fe1ef96bd12b5134

RESEARCH PRODUCT

Intraocular Pressure Telemetry for Managing Glaucoma during the COVID-19 Pandemic

Robert N. WeinrebEsther M. HoffmannLars ChoritzInga Kersten-gomezPeter SzurmanKaweh Mansouri

subject

MaleAgingIntraocular pressuregenetic structuresCross-sectional studyIntraocular pressureOffice visitsGlaucomaComorbidityNeurodegenerative01 natural sciences0302 clinical medicineTelemetryTelemetryProspective StudiesProspective cohort studyCOVID-19 coronavirus disease 2019Sensor systemInfectiousGeneral MedicineEquipment DesignMiddle AgedFemaleSwitzerlandmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)MonitoringClinical Trials and Supportive ActivitiesBioengineeringTonometry03 medical and health sciencesTonometry OcularDisease TransmissionClinical ResearchOcularOphthalmologyLockdownmedicineDisease Transmission InfectiousHumans0101 mathematicsEye Disease and Disorders of VisionPandemicsbusiness.industrySARS-CoV-2IOP010102 general mathematicsNeurosciencesCOVID-19Glaucomamedicine.diseaseIOP intraocular pressureeye diseasesFull-length articles and Review articlesUnited KingdomCross-Sectional Studies030221 ophthalmology & optometrysense organsbusinessFollow-Up Studies

description

Purpose To evaluate in glaucoma patients the feasibility and use of remote monitoring of intraocular pressure (IOP) with an implanted telemetry sensor during the coronavirus disease 2019 (COVID-19) lockdown. Design Cross-sectional study. Participants Patients previously implanted with a telemetric IOP sensor (Eyemate; Implandata GmbH) were included. Methods Intraocular pressure measurements acquired by the patients during the lockdown were collected by physicians who were located remotely. A questionnaire was sent to 10 participating study centers to evaluate the clinical impact of remote monitoring of IOP via the IOP sensor system. Main Outcome Measures Number of patients who obtained home IOP measurements. Results Data were available from all centers and from 37 eyes of 37 patients (16 patients with a sulcus-based sensor and 21 patients with a suprachoroidal sensor). Thirty-four patients obtained IOP measurements during the lockdown. Mean age of the patients was 69.3 ± 9.6 years, and 48.6% were women. A total of 8415 IOP measurements from 370 measurement days were obtained. Based on remote IOP measurements, treatment was changed in 5 patients. In another 5 patients, treatment change was considered when physicians received the IOP measurements after the lockdown. Nine of the 10 study centers judged remote IOP measurements to have a clinical impact. Conclusions These results show the feasibility of patient-acquired measurement of IOP in conjunction with remote IOP monitoring by physicians with an implantable sensor. The data obtained impacted clinical decision making, including adjustment of ocular hypotensive therapy and avoiding unnecessary office visits during the COVID-19 pandemic.

10.1016/j.ogla.2020.12.008http://europepmc.org/articles/PMC7860938